Novavax Inc
NASDAQ:NVAX
Novavax Inc
NASDAQ:NVAX
Price:
4.93 USD
4.67%
Market Closed
Updated:
May 4, 2024
Novavax Inc
Revenue
|
Novavax Inc
Revenue Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Novavax Inc
NASDAQ:NVAX
|
Revenue
$983.7m
|
CAGR 3-Years
27%
|
CAGR 5-Years
96%
|
CAGR 10-Years
47%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Novavax Inc
Revenue Breakdown
Breakdown by Geography
Novavax Inc
Novavax Inc
Not Available
Breakdown by Segments
Novavax Inc
Novavax Inc
|
Total Revenue:
983.7m
USD
|
|
Product:
531.4m
USD
|
|
Grant:
427.3m
USD
|
|
Royalties And Other:
25m
USD
|
See Also
What is Novavax Inc's Revenue?
Revenue
983.7m
USD
983.7m
USD
Based on the financial report for Dec 31, 2023, Novavax Inc's Revenue amounts to 983.7m USD.
What is Novavax Inc's Revenue growth rate?
Revenue CAGR 10Y
47%
47%
Over the last year, the Revenue growth was -50%. The average annual Revenue growth rates for Novavax Inc have been 27% over the past three years , 96% over the past five years , and 47% over the past ten years .
You don't have any saved screeners yet
